Source: International Congress 2017 – A novel approach to lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
P. Adusumilli (New York, United States of America). CAR T-cell therapy for lung cancer. International Congress 2017 – A novel approach to lung cancer

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021 Ras peptide-specific vaccination in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 Re-challenge of immunotherapy in a lung cancer patient Source: Virtual Congress 2021 – Lung cancer grand round Year: 2021 Boosting immunotherapy in lung cancer  Source: International Congress 2017 – ME9 Boosting immunotherapy in lung cancer Year: 2017 Association of antiPD1 immunotherapy with immunogenic cell death-inducing chemotherapy in a murine model of squamous cell lung cancer Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 Targeted therapy for lung cancer Source: Eur Respir J 2015; 46: 1239-1241 Year: 2015 Immunotherapies for lung cancer Source: International Congress 2018 – ME12 Immunotherapies for lung cancer FULLY BOOKED Year: 2018 Targeted therapy in non-small cell lung cancer Source: Breathe 2012; 8: 206-215 Year: 2012 Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer Source: Eur Respir J 2015; 46: 1762-1772 Year: 2015 Chemotherapy for small cell lung cancer Source: Annual Congress 2006 - PG12 - Small cell lung cancer management Year: 2006 How to evaluate the immune status of lung cancer patients before immunotherapy Source: Breathe, 13 (4) 291; 10.1183/20734735.001917 Year: 2017 Surgical treatment of nonsmall cell lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=170 Year: 2001 Proliferative activity of non-small cell lung cancer after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005 Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019 Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy Source: Eur Respir J 2012; 39: 1437-1442 Year: 2012 New treatment options for nonsmall cell lung cancer and small cell lung cancer Source: Annual Congress 2006 - PG12 - Small cell lung cancer management Year: 2006 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 New chemotherapeutic agents Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=259 Year: 2001